

In the claims:

1.-6. (canceled)

7. (Currently amended) A ~~drug composition~~ comprising a 2-imidazolyl disulfide ~~and an acceptable carrier, said 2-imidazolyl disulfide being that~~ is useful in reducing or eliminating thioredoxin-associated apoptosis inhibition and a ~~pharmaceutically acceptable carrier~~.

8. (Currently amended) A ~~drug composition~~ comprising a 2-imidazolyl disulfide ~~and an acceptable carrier, said 2-imidazolyl disulfide being that~~ is useful in inhibiting thioredoxin stimulated cell growth and a ~~pharmaceutically acceptable carrier~~.

9. (Currently amended) The ~~drug composition~~ of claim 7, wherein said 2-imidazolyl disulfide ~~compound~~ is 1-methylpropyl 2-imidazolyl disulfide.

10. (Currently amended) The ~~drug composition~~ of claim 8, wherein said 2-imidazolyl disulfide ~~compound~~ is 1-methylpropyl 2-imidazolyl disulfide.

11. (New) The drug of claim 7, wherein said 2-imidazolyl disulfide inhibits tumor growth.

12. (New) The drug of claim 8, wherein said 2-imidazolyl disulfide inhibits tumor growth.

13. (New) The drug of claim 7, wherein said 2-imidazolyl disulfide inhibits thioredoxin.

14. (New) The drug of claim 8, wherein said 2-imidazolyl disulfide inhibits thioredoxin.

15. (New) The drug of claim 7, wherein said 2-imidazolyl disulfide irreversibly binds to thioredoxin.

16. (New) The drug of claim 8, wherein said 2-imidazolyl disulfide irreversibly binds to thioredoxin.

17. (New) The drug of claim 7, wherein said 2-imidazolyl disulfide irreversibly binds to Cys⁷³ of thioredoxin.

18. (New) The drug of claim 8, wherein said 2-imidazolyl disulfide irreversibly binds to Cys⁷³ of thioredoxin.